BioScrip Stock Analysis, Valuation (NASDAQ:BIOS)

Add to My Stocks
$2.99 $0.11 (3.55%) BIOS stock closing price Aug 16, 2017 (Closing)
Watch Robo Advisor Video of BIOS Stock Analysis
BioScrip
Updated on : Aug 16, 2017
previous close
BIOS 3 (0%)
S&P 500 2468.1 (0%)
Closing Price On: Aug 16, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Outpatient-Home care
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q2
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-6.3%
Operating Profit
Operating Margin:
-0.5%
Sector Average:
-2.2%
5 Quarter Net Profit
Net Margins
2017-Q2
%
LTM Margin
Debt/Equity Ratio
Debt:
477.4M
Debt/Equity Ratio:
 35.68
Compared to the industry
Cash Flow
Operating cash flow:
$6M
Net Income:
-$29.2M
PROS      CONS
PS Valuation
Recent Growth
Long Term Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
BIOS PS :
0.4
Industry PS :
5
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-0.7%
Return on Equity:
-206.8%
Free Cash Flow Margin:
1.6%
Double Tap To Exit Full Screen
0:00
/

BioScrip Analysis Video

81 6 2

View BioScrip stock analysis video. This is our BIOS analyst opinion covering the buy and sell arguments for BIOS stock.

BioScrip Inc Stock Rating (2.4/5)

Our BioScrip stock opinion is based on fundamentals of the company. This BioScrip stock analysis is based on latest 2017 Q2 earnings. The stock price analysis takes into account the company's valuation metrics.

Should you buy BIOS stock?

  • BIOS stock is trading at a favorable price to sales multiple of 0.4 as against the Medical-Outpatient-Home care industry average multiple of 5.

Should you sell BIOS stock?

  • BioScrip sales declined by -6.2% year on year in 2017 Q2.
  • The company saw an average annual sales decline of -6.3% in sales over the last 5 years.
  • BioScrip registered a negative operating margin of -0.5% (average) over the Trailing Twelve Months (TTM).
  • Over the last 12 months, BioScrip had an average Net loss of -8%.
  • BioScrip is debt laden and has a high debt/equity ratio of  35.68.
  • The company does not have profits. Hence the PE ratio is meaningless for BIOS stock.
  • BioScrip has a negative ROIC (Return on Invested Capital) of -0.7%.
  • A negative ROE of -206.8% indicates that the company is not able to generate profits with the money shareholders have invested.

Comments on this video and BioScrip stock